The company's challenges might not be insurmountable, but they are serious enough to warrant a healthy dose of skepticism.

Tandem Diabetes TNDM is gaining from continued product innovations. Yet, rising costs put pressure on margins. The stock carries a Zacks Rank #3 (Hold). Tandem Diabetes is driving transformative ...

Helping toddlers manage their Type 1 diabetes—typically a difficult task, due to their constant growth and development, not to mention fussiness—may now be a bit easier. The FDA has expanded its ...

Tandem Diabetes Care, Inc.’s TNDM impressive international expansion is expected to bolster growth in the upcoming quarters. The company’s impressive strategic initiatives provide a favorable ...

Tandem Diabetes Care has received the Food and Drug Administration’s green light for the Tandem Mobi insulin pump for people with diabetes aged 6 years old and older. The Tandem Mobi is fully ...

The next big thing on Tandem Diabetes Care’s technology slate is actually a very small thing. The Mobi insulin pump—which is the company's smallest device to date and, it claims, the smallest ...

Tandem Diabetes Care's t:slim X2 Insulin Pump Automated Insulin Delivery System is now the first to incorporate the Abbott FreeStyle Libre 2 Plus Sensor for users in the United States. The FreeStyle ...

Though Tandem Diabetes has made a splash in the insulin pump market as the latest entrant in the US, the firm is still endeavoring to establish itself as a major competitor. On this rather lengthy ...

Good day and thank you for standing by. Welcome to the Tandem Diabetes Care Q3 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Please be advised that today's ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it achieved ISO/IEC 27001:2022 Certification from ...